Sapropterin hydrochloride: enzyme enhancement therapy for phenylketonuria
Phenylketonuria (PKU) is an inherited disorder of amino acid metabolism caused by deficiency of the enzyme phenylalanine hydroxylase (PAH). Historically PKU was a common genetic cause of severe learning difficulties and developmental delay, but with the introduction of newborn screening and early di...
Main Author: | Robin Lachmann |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2011-06-01
|
Series: | Therapeutic Advances in Endocrinology and Metabolism |
Online Access: | https://doi.org/10.1177/2042018811402248 |
Similar Items
-
New era in treatment for phenylketonuria: Pharmacologic therapy with sapropterin dihydrochloride
by: Cary O Harding
Published: (2010-08-01) -
Metabolic Control in Patients With Phenylketonuria Pre- and Post-Sapropterin Loading Test
by: Catarina Sousa Barbosa BSc, et al.
Published: (2018-08-01) -
Pretreatment cognitive and neural differences between sapropterin dihydrochloride responders and non-responders with phenylketonuria
by: Zoë Hawks, et al.
Published: (2017-09-01) -
First Japanese case of maternal phenylketonuria treated with sapropterin dihydrochloride and the normal growth and development of the child
by: Hiromi Nyuzuki, et al.
Published: (2019-12-01) -
Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial
by: Ania C. Muntau, et al.
Published: (2021-08-01)